Home

This technology uses a single-chain IgA1 antibody delivered by DNA or RNA to enable the body to produce its own protection against dengue and Zika viruses, offering rapid, safe, and scalable prevention and treatment without risk of antibody-dependent enhancement. Background:
Flavivirus infections, including those caused by dengue and Zika viruses, represent a significant global health concern, affecting billions of people and resulting in hundreds of millions of infections annually. These diseases can lead to severe illness and death, particularly in regions where healthcare resources are limited and outbreaks are frequent. The lack of effective vaccines or therapeutics for many at-risk populations underscores the urgent need for new approaches to both prevent and treat these infections. Monoclonal antibody therapies have shown promise in neutralizing viral pathogens and providing immediate immunity, making them attractive candidates for outbreak response and prophylactic use in vulnerable populations. However, current monoclonal antibody therapies face several critical limitations that hinder their widespread deployment during flavivirus outbreaks. Traditional antibodies are complex molecules composed of two heavy and two light chains, requiring intricate and costly manufacturing processes in specialized facilities. These therapies are typically administered via intravenous infusion, necessitating trained personnel and advanced medical infrastructure, which are often unavailable in outbreak settings or resource-limited regions. Additionally, IgG-based antibodies carry the risk of Antibody Dependent Enhancement (ADE), a phenomenon that can worsen disease severity in individuals with partial immunity, further complicating their use for dengue and related viruses. Existing nucleic acid-based delivery systems are also challenged by the need to co-express multiple antibody chains, reducing efficiency and scalability for rapid response.Technology Overview:  
This technology is a single-chain recombinant IgA1 monoclonal antibody construct specifically engineered for nucleic acid-based delivery to combat flavivirus infections such as dengue and Zika virus. Unlike conventional monoclonal antibody therapies, which require complex manufacturing and infusion processes, this solution utilizes a single-chain format that fuses the heavy and light chain variable regions into one polypeptide, linked to a truncated IgA1 Fc region. This design allows the antibody to be encoded by a single DNA or RNA molecule, enabling direct in vivo expression after administration. The optimized construct incorporates an engineered leader sequence, a GS3 linker, a human IgG1 hinge, and the Ca2 and Ca3 domains of the human IgA1 Fc, ensuring efficient production and robust neutralizing activity against all four dengue virus serotypes. Importantly, the IgA1 isotype was chosen because it does not mediate Antibody Dependent Enhancement (ADE), a major safety concern in dengue treatment. What differentiates this technology is its novel single-chain IgA1 architecture, which is the first of its kind, as previous single-chain antibody constructs have focused on the IgG1 isotype. The strategic molecular design (combining variable regions, linker, and hinge domains) enables high-level expression and functional activity from a single nucleic acid vector, greatly simplifying manufacturing and deployment. Its compatibility with DNA or RNA delivery platforms means that the antibody can be rapidly and cost-effectively produced and administered, bypassing the need for traditional biomanufacturing and infusion infrastructure. This approach not only addresses the urgent need for safe and effective flavivirus therapeutics but also enables rapid outbreak response, making it suitable for use in travelers, military personnel, residents in endemic regions, and for targeted containment of transmission clusters.https://suny.technologypublisher.com/files/sites/adobestock_56423730.jpegAdvantages:  
•    Enables rapid, scalable, and cost-effective production and delivery of therapeutic antibodies via nucleic acid vectors (DNA/RNA).
•    Single-chain IgA1 antibody format simplifies manufacturing by encoding both heavy and light chain variable regions in a single polypeptide.
•    Provides broad neutralization against all four dengue virus serotypes, addressing a major global health challenge.
•    IgA1 isotype avoids Antibody Dependent Enhancement (ADE), improving safety compared to traditional IgG antibodies.
•    Facilitates immediate immunity for prophylactic and therapeutic use in diverse populations including travelers, military personnel, and residents in endemic areas.
•    Eliminates need for specialized infusion equipment, enabling easier and faster deployment during outbreaks.
•    Preserves unique IgA1 effector functions while optimizing expression and function through engineered molecular design. Applications:  
•    Dengue outbreak rapid response
•    Traveler prophylactic immunization
•    Military deployment disease prevention
•    Close contact post-exposure prophylaxis
•    Endemic region population protection Intellectual Property Summary:
Know-how basedStage of Development:
TRL 3 Licensing Status:
This technology is available for licensing.

This technology is a single-chain IgA1 antibody delivered by DNA or RNA, enabling the body to produce its own dengue-neutralizing antibodies safely and quickly, without the risk of worsening infection, for rapid prevention and treatment of flavivirus diseases. Background:
The field of flavivirus therapeutics, particularly for diseases like dengue, is of critical global importance due to the widespread prevalence and significant morbidity and mortality associated with these infections. Dengue alone threatens nearly 40% of the world’s population, causing hundreds of millions of infections each year. Despite this immense burden, effective prevention and treatment options remain limited. The absence of broadly effective vaccines, especially for individuals without prior exposure, and the lack of approved monoclonal antibody therapies highlight a pressing need for innovative solutions. Rapid, scalable, and easily deployable interventions are especially crucial during outbreaks, when traditional manufacturing and distribution methods for biologics can be too slow or resource-intensive to meet urgent demand. Current approaches to monoclonal antibody therapy for flaviviruses face several significant challenges. Conventional antibodies are complex molecules composed of separate heavy and light chains, requiring intricate and costly manufacturing processes, as well as specialized equipment for administration, such as intravenous infusions. These logistical hurdles hinder timely deployment, particularly in resource-limited settings or during sudden outbreaks. Furthermore, the predominant use of the IgG isotype in antibody therapies introduces a major safety concern: Antibody Dependent Enhancement (ADE), where antibodies can paradoxically worsen infection in partially immune individuals. This phenomenon has stymied the development of safe and effective antibody-based interventions for dengue, as IgG antibodies can facilitate viral entry into host cells and exacerbate disease severity. As a result, there is a critical unmet need for antibody-based therapies that are both safe from ADE and compatible with rapid, cost-effective, and scalable delivery platforms.Technology Overview:  
This technology is a single-chain recombinant IgA1 monoclonal antibody specifically engineered for the treatment and prevention of flavivirus infections, with a primary focus on dengue virus. The construct is designed as a single polypeptide that fuses the heavy and light chain variable regions via a GS3 linker, and incorporates an optimized leader sequence for efficient secretion, a human IgG1 hinge region for flexibility, and the Ca2 and Ca3 domains of the human IgA1 Fc region. This configuration enables the antibody to be delivered through nucleic acid vectors, such as DNA or RNA, allowing the patient’s own cells to produce the therapeutic antibody in vivo. The IgA1 isotype is chosen for its ability to neutralize all four dengue virus serotypes while avoiding Antibody Dependent Enhancement (ADE), a significant safety concern associated with IgG antibodies in dengue therapy. What differentiates this technology is its innovative single-chain design, which overcomes the complexity and inefficiency of delivering separate heavy and light chain genes typically required for monoclonal antibody therapies. By utilizing the IgA1 isotype and a streamlined genetic construct, the solution not only mitigates the risk of ADE but also enables rapid, scalable, and cost-effective production and deployment through nucleic acid delivery platforms. This approach eliminates the need for traditional antibody manufacturing and infusion infrastructure, making it especially valuable for rapid response during outbreaks and in resource-limited settings. Its specific applicability to expecting mothers addresses a unique and vulnerable population. https://suny.technologypublisher.com/files/sites/adobestock_518283890.jpeg Advantages:  
•    Enables in vivo production of therapeutic antibodies via nucleic acid delivery, reducing manufacturing complexity and cost.
•    Neutralizes all four dengue virus serotypes effectively, providing broad protection.
•    IgA1 isotype avoids Antibody Dependent Enhancement (ADE), enhancing safety compared to IgG antibodies.
•    Single-chain design fuses heavy and light chain variable regions, simplifying gene delivery and expression.
•    Rapid and scalable deployment potential for outbreak response without need for specialized infusion equipment.
•    Versatile applications including prophylaxis for travelers, military personnel, endemic populations, and outbreak containment.
•    Optimized molecular design ensures efficient secretion, flexibility, and preserved antibody effector functions. Applications:  
•    Prophylactic treatment for travelers
•    Outbreak containment in endemic regions
•    Rapid deployment for military personnel
•    Immediate post-exposure prophylaxis Intellectual Property Summary:
Know-how basedStage of Development:
TRL 2Licensing Status:
This technology is available for licensing.
 

This is a simple, low-cost device using absorbent material and nested tubes to collect clean, mucous-free oral fluid samples by centrifugation, making sample collection easier, more hygienic, and affordable for labs and research. Background:
Oral fluid collection is an essential process in various fields, including clinical diagnostics, biomedical research, and educational laboratory exercises. Saliva contains numerous biomarkers that can provide valuable information about a person's health, making it a non-invasive and accessible alternative to blood sampling. In undergraduate biochemistry labs, for example, students often need to collect their own oral fluid samples for experiments involving enzymes or other analytes. However, the process of collecting these samples must be hygienic, straightforward, and comfortable for users, especially in group settings where embarrassment or discomfort can hinder participation and learning outcomes. Current approaches to oral fluid collection typically involve either expectorating (spitting or drooling) directly into a tube or using commercial collection devices. The former method is often perceived as unpleasant or embarrassing, particularly in classroom or group environments, and it tends to yield samples that are viscous and contaminated with mucous, making them difficult to handle and analyze in laboratory settings. On the other hand, commercially available collection devices, while more effective at producing cleaner samples, are prohibitively expensive for routine or large-scale use, especially in educational contexts with limited budgets. These challenges highlight the need for a cost-effective, user-friendly solution that can reliably produce high-quality, mucous-free oral fluid samples without causing discomfort or incurring significant expense.Technology Overview:  
This technology is a cost-effective and user-friendly device designed for the hygienic collection of oral fluid samples. It features two nested tubes and a ball of absorbent material, which may include a handle for ease of use. To operate, the user places the absorbent material in their mouth to collect oral fluid, then transfers it into the inner tube of the device. The entire assembly is then subjected to centrifugation, which uses centrifugal force to expel the liquid from the absorbent material. The expelled liquid passes through a small hole in the inner tube and collects in the base of the outer tube, resulting in a liquid-only oral fluid sample that is free from mucous and easy to handle in laboratory settings. The device is assembled from inexpensive, readily available components, with a total cost of less than $0.25 per unit. What differentiates this technology is its unique combination of simplicity, affordability, and effectiveness in producing high-quality, mucous-free oral fluid samples. Unlike traditional methods such as spitting or drooling into a tube—which can be uncomfortable, embarrassing, and yield viscous samples that are difficult to process—this device streamlines the collection process and ensures a clean, liquid sample suitable for laboratory analysis. Commercial alternatives are significantly more expensive, often costing several dollars per device, while this solution can be assembled from common materials, making it accessible for educational, clinical, and research applications. Its robust and foolproof design has been validated by undergraduate students with no collection failures, highlighting its reliability and scalability for widespread use in settings that require efficient and hygienic oral fluid collection. https://suny.technologypublisher.com/files/sites/adobestock_234267306.jpegAdvantages:  
•    Cost-effective design with assembly cost under $0.25 per device
•    Produces mucous-free, liquid-only oral fluid samples for easier laboratory handling
•    Simple and user-friendly, reducing discomfort and embarrassment during sample collection
•    Utilizes readily available components, enabling easy and scalable production
•    Reliable and foolproof sample collection demonstrated with no failures in student use
•    Applicable for educational labs, clinical diagnostics, and salivary biomarker research
•    Compact and efficient use of centrifugal force to separate fluid from absorbent material Applications:  
•    Educational laboratory sample collection
•    Clinical diagnostic saliva testing
•    Salivary biomarker research
•    Point-of-care oral fluid screening Intellectual Property Summary:
Patent PendingStage of Development:
TRL 6Licensing Status:
This technology is available for licensing.

HistoTME is an AI software that predicts the tumor microenvironment’s molecular makeup from standard pathology images, helping identify lung cancer patients likely to benefit from immunotherapy without needing costly molecular tests. Background:
The tumor microenvironment (TME) plays a crucial role in the progression and treatment response of cancers, particularly non-small cell lung cancer (NSCLC). As immunotherapies such as immune checkpoint inhibitors (ICIs) become increasingly central to cancer care, the ability to accurately characterize the TME is essential for predicting which patients will benefit from these treatments. Traditionally, the assessment of TME relies on molecular assays, such as RNA sequencing or immunohistochemistry, which provide insights into the immune landscape of tumors. However, these tests are often expensive, require specialized equipment and expertise, and may not be accessible in all clinical settings. The growing demand for precision oncology has highlighted the need for more accessible, cost-effective, and scalable methods to evaluate the TME and guide immunotherapy decisions. Current approaches to TME characterization face several significant limitations. Biomarkers like PD-L1 expression, while widely used, are not always reliable predictors of response to ICIs, especially in patients with low PD-L1 levels. Molecular assays, though informative, are resource-intensive and may not be feasible in many healthcare environments due to cost, infrastructure, or insurance coverage constraints. Additionally, these methods often require fresh or high-quality tissue samples, which are not always available, and involve lengthy turnaround times that can delay treatment decisions. Digital pathology offers a potential alternative, but existing computational tools typically depend on expert pathologist annotation or lack the ability to directly infer molecular features from routine histopathology slides, limiting their clinical utility and scalability.Technology Overview:  
HistoTME is a software-based artificial intelligence tool designed to predict the molecular composition of the tumor microenvironment (TME) directly from standard hematoxylin and eosin (H&E)-stained histopathology images. The system operates through a sophisticated two-step pipeline: first, it uses the UNI foundation model to extract detailed image features, which are then processed by a multitask-attention-based multiple instance learning (AB-MIL) framework to generate prediction scores and heatmaps. In the second step, HistoTME applies clustering analysis and a two-step random forest classification algorithm to categorize patients into clinically relevant TME subtypes—immune-desert or immune-inflamed. This approach enables the prediction of patient response to immune checkpoint inhibitor (ICI) therapy, using only digital pathology slides, without the need for expert annotation or costly molecular assays. What differentiates HistoTME is its ability to serve as a digital biomarker, offering a scalable, cost-effective alternative to traditional molecular testing for immunotherapy stratification. Unlike conventional biomarkers such as PD-L1 expression, which often lack predictive power in patients with low expression levels, HistoTME leverages routinely available pathology images and advanced AI to infer molecularly defined TME subtypes. The tool was trained and validated on a large, multi-modal dataset of over 650 lung cancer patients with matched histopathology and RNA sequencing data, ensuring robust performance and clinical relevance. Its design eliminates the need for specialized molecular infrastructure, making it particularly valuable for resource-limited settings. Additionally, the integration of interpretability features, such as spatial heatmaps, enhances clinical trust and usability, positioning HistoTME as a transformative solution in the field of computational pathology and precision oncology. https://suny.technologypublisher.com/files/sites/adobestock_553686090.jpegAdvantages:  
•    Enables prediction of tumor microenvironment molecular composition directly from standard H&E-stained histopathology images without requiring molecular testing.
•    Improves identification of non-small cell lung cancer (NSCLC) patients likely to benefit from immune checkpoint inhibitor (ICI) therapy, enhancing treatment personalization.
•    Provides a cost-effective and accessible alternative to expensive molecular assays, suitable for resource-limited medical centers.
•    Utilizes advanced AI techniques combining foundation models and multiple instance learning for accurate and interpretable predictions with spatial heatmaps.
•    Classifies patients into clinically relevant immune-inflamed or immune-desert TME subtypes, aiding clinical decision-making.
•    Validated on a large multi-modal dataset with matched histopathology and RNA sequencing data, ensuring robust performance and clinical relevance.
•    Does not require expert pathologist annotation, facilitating scalable deployment in diverse clinical settings. Applications:  
•    Immunotherapy response prediction
•    Digital pathology workflow integration
•    Cost-effective biomarker development
•    Resource-limited cancer diagnostics Intellectual Property Summary:
Patent PendingStage of Development:
TRL 5Licensing Status:
This technology is available for licensing.